Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

The phase 3 SONIA trial showed deferring CDK4/6 inhibitor treatment may not compromise HRQOL in patients with HR-positive/HER2-negative advanced breast cancer.

Discontinuation rates were 19% for abemaciclib. 6 ILD was slightly higher here, 3.3% was reported in the monarchE trial, so we can’t forget about pneumonitis with CDK4/6 inhibitors and have to bear ...

A new analysis of the SONIA trial found that the timing of CDK4/6 inhibitor use in patients with advanced hormone receptor-positive, HER2-negative breast cancer did not affect their health-related ...

There is a huge need to identify patients who may or may not benefit from adding CDK4/6 inhibitors at the time of metastatic diagnosis to guide escalation and de-escalation strategies in advance ...

NEW RESEARCH presented at the San Antonio Breast Cancer Symposium (SABCS) has shown that an advanced machine learning model that integrates clinical and genomic data to predict how patients with ...

According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in HR-positive, HER2-negative metastatic breast cancer. In a retrospective study ...

Here, we address the role of cyclin-dependent kinase inhibitors (CDKIs) in the later stages of dorsal cortical development. We find that the CDKIs p18 and p27 are upregulated at the onset of astrocyte ...

Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen receptor-positive/HER2-negative metastatic breast ...

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University in ...